Since nocturnal hypoxemia occurs early in CF and has been associated with inflammation, we suggest that the benefits of precocious and long-term treatment with CFTR modulators could be greater than expected, interfering with the vicious cycle of inflammation-impaired mucociliary clearance infection typical of CF [70,71]. The gene discussed is CFTR; the disease is cystic fibrosis.